Strana 1 z 18 Výsledek
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2012/081744 filed Dec. 7, 2012, claiming priority based on Japanese Patent Application No. 2011-268561 filed Dec. 8, 2011, the contents of all of which are incorporated herein by
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2010/052114 filed Feb. 5, 2010, claiming priorities based on Japanese Patent Application Nos. 2009-25462 filed Feb. 6, 2009 and 2009-146735 filed Jun. 19, 2009, the contents of all of
The present invention relates to the field of bioorgmic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as
The present invention relates to the field of bioorganic chemistry and concerns N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof, novel processes for synthesis of said compounds as well as pharmaceutical compositions based on them and use thereof in medicine as
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2008/070712 filed Nov. 13, 2008, claiming priorities based on Japanese Patent Application No. 2007-294040 filed Nov. 13, 2007 and 2008-153736 filed Jun. 12, 2008, the contents of all
BACKGROUND ART
Histamine is usually stored within intracellular granules in mast cells, lung, liver and gastric mucosa, etc. In response to external stimuli such as antigen binding to cell surface antibody, histamine is released into the extracellular environment. For example, when mast cells are
BACKGROUND ART
Histamine is usually stored within intracellular granules in mast cells, lung, liver and gastric mucosa, etc. In response to external stimuli such as antigen binding to cell surface antibody, histamine is released into the extracellular environment. For example, when mast cells are
BACKGROUND OF THE INVENTION
This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors using such compounds.
The entire disclosure of parent application 60/541,151 filed Feb. 2, 2004 is fully incorporated herein by reference thereto.
BACKGROUND OF THE INVENTION
This invention is directed to compounds of formula I described herein, to pharmaceutical composition comprising such compounds, and to methods of
BACKGROUND OF THE INVENTION
This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, to a process of preparation of such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing
BACKGROUND OF THE INVENTION
This invention is directed to compounds of formula I described herein, to a pharmaceutical composition comprising such compounds, to a process of preparation of such compounds, and to methods of treatment of disorders or conditions that may be treated by antagonizing
The present invention is directed to the tosylate salt of the compound of formula 1, as described herein, to a pharmaceutical composition comprising this salt, and to methods of treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H.sub.3) receptors using the
The present invention is directed to the tosylate salt of the compound of formula 1 as described herein, to a pharmaceutical composition comprising this preferred salt, and to methods of treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H.sub.3) receptors using
The present invention relates to compounds that are inhibitors of cysteine proteinases, pharmaceutical compositions containing said compounds, and their use in therapy. More specifically, the invention relates to compounds that are inhibitors of cathepsin S, a cysteine proteinase of the CA clan.